Thus, the protection afforded by ERp57 overexpression over the NMJ is likely to be unrelated to the modulation of abnormal protein aggregation, suggesting that distinct molecular mechanisms operate in ALS pathophysiology depending on the disease stage. The gene discussed is PDIA3; the disease is amyotrophic lateral sclerosis.